Application is based on data from the pivotal Phase 3 AENEAS trial evaluating aumolertinib as…
Arboretum_JDDecember 2, 2022
EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative…
Arboretum_JDJune 14, 2022
EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative…
Arboretum_JDMay 27, 2022
EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative…
Arboretum_JDMarch 23, 2022
EQRx, Inc. (Nasdaq: EQRX) a new type of pharmaceutical company committed to developing and delivering…
Casey FrushourJanuary 18, 2022
EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering…
Casey FrushourJanuary 10, 2022
CM Life Sciences III (Nasdaq: CMLT, CMLTW, CMLTU), a life science-focused special purpose acquisition company,…
Arboretum_JDDecember 17, 2021
EQRx, a new type of pharmaceutical company committed to developing and delivering important new medicines…
Arboretum_JDDecember 2, 2021
EQRx Announces Partnership Agreement with Abdul Latif Jameel Health to Commercialize Lead Oncology Programs in…
Arboretum_JDNovember 22, 2021
